Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)’s stock price has decreased by -3.57 compared to its previous closing price of 20.14. However, the company has seen a -6.54% decrease in its stock price over the last five trading sessions. businesswire.com reported 2024-09-23 that PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end of 2024 to initiate a clinical trial for its second obesity candidate, ARO-ALK7. “Arrowhead’s two investigational R.
Is It Worth Investing in Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Right Now?
The 36-month beta value for ARWR is also noteworthy at 0.96. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ARWR is 118.50M, and at present, short sellers hold a 7.64% of that float. The average trading volume of ARWR on September 26, 2024 was 1.03M shares.
ARWR’s Market Performance
The stock of Arrowhead Pharmaceuticals Inc. (ARWR) has seen a -6.54% decrease in the past week, with a -21.38% drop in the past month, and a -26.05% fall in the past quarter. The volatility ratio for the week is 4.13%, and the volatility levels for the past 30 days are at 5.15% for ARWR. The simple moving average for the last 20 days is -11.19% for ARWR stock, with a simple moving average of -28.51% for the last 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Goldman repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Goldman is $31 based on the research report published on June 05, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $29. The rating they have provided for ARWR stocks is “Buy” according to the report published on December 04th, 2023.
Citigroup gave a rating of “Neutral” to ARWR, setting the target price at $33 in the report published on September 19th of the previous year.
ARWR Trading at -20.35% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.24% of loss for the given period.
Volatility was left at 5.15%, however, over the last 30 days, the volatility rate increased by 4.13%, as shares sank -18.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.26% lower at present.
During the last 5 trading sessions, ARWR fell by -6.54%, which changed the moving average for the period of 200-days by -20.83% in comparison to the 20-day moving average, which settled at $21.64. In addition, Arrowhead Pharmaceuticals Inc. saw -36.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Oliver Tracie, who sale 9,394 shares at the price of $25.28 back on Jul 02 ’24. After this action, Oliver Tracie now owns 127,107 shares of Arrowhead Pharmaceuticals Inc., valued at $237,480 using the latest closing price.
Vakiener Victoria, the Director of Arrowhead Pharmaceuticals Inc., sale 1,799 shares at $23.31 during a trade that took place back on May 02 ’24, which means that Vakiener Victoria is holding 30,205 shares at $41,935 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -27.85 for the present operating margin
- 0.11 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc. stands at -27.41. The total capital return value is set at -0.7. Equity return is now at value -154.92, with -64.14 for asset returns.
Based on Arrowhead Pharmaceuticals Inc. (ARWR), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at -1.03. The debt to equity ratio resting at 1.03. The interest coverage ratio of the stock is -23.83.
Currently, EBITDA for the company is -188.16 million with net debt to EBITDA at -0.74. When we switch over and look at the enterprise to sales, we see a ratio of 142.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.65.
Conclusion
In summary, Arrowhead Pharmaceuticals Inc. (ARWR) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
